European Subtype Report: Hodgkin Lymphoma

HL is primarily a curable cancer and with current treatments, 80% to 90% of patients can achieve permanent remission. The mainstay of treatment is multi-agent chemotherapy often in combination with radiation therapy. With high treatment responses, focus is now being made to improve long term morbidity issues.

Despite the success stories, there are still concerns:

  • The long-term effects of treatment impacting overall quality of life. Patients are dealing with the effects of treatment for many years.
  • Treating relapsed/refractory disease.

As well, there are discrepancies in incidence and mortality in Europe and continuing inequalities regarding treatment access.

While the overall survival rate for HL is good in relation to many other lymphomas, there is still work to do to ensure all patients can be effectively treated and enjoy a good quality of life post-treatment.

 

hl european report

Click here to view or download the report.

 

Global Database

Information by country, region and/or subtype on treatments, clinical trials and incidence/mortality rates.

Resource Library

Over 2,000 pieces of information on lymphoma diagnosis, treatment, research, support and lifestyle.

logo europe

WEIGH-IN WEDNESDAY

Did you participate in World Lymphoma Awareness Day on September 15?

IN THE NODE

Updates

 

The information on this website is for general use only. Please consult your physician if you think you may have lymphoma or
require more detailed information on the best course of treatment for you.

Our website does not host any form of advertisement. Last updated: 03/27/18. Copyright © 2018 Lymphoma Coalition. All rights reserved.